lapatinib has been researched along with Cancer of Lung in 66 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (10.61) | 29.6817 |
| 2010's | 48 (72.73) | 24.3611 |
| 2020's | 11 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Byun, JY; Cha, MY; Choi, KJ; Jung, YH; Kang, SJ; Kim, MS; Lee, GS; Lee, HJ; Lee, KO; Park, SB; Song, JY | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Dahal, A; Gu, X; Jois, S; Mattheolabakis, G; Singh, SS; Withers, S | 1 |
| Chen, J; Li, W; Ouyang, L; Shuai, W; Tan, L; Wang, C; Wang, G; Wang, X; Wang, Y; Zhang, J; Zhang, Z | 1 |
| Bao, R; Cai, H; Gu, Y; Hu, F; Li, C; Lin, Q | 1 |
| Feng, M; Li, Q; Liao, W; Qian, Z; Wen, F; Wu, Q; Yang, Y | 1 |
| Akash, MSH; Al Haddad, AHI; Alamri, A; Awadh, AAA; Fatease, AA; Hussain, M; Hussain, N; Rehman, K; Sabei, FY; Safhi, AY; Said, ASA; Tariq, M | 1 |
| Abdel-Fattah, MM; Amin, NH; El-Saadi, MT; Mohammed, AA; Said, EG | 1 |
| Szymaszek, Ż; Twardowska, M; Uram, Ł; Walczak, M; Wołowiec, S; Wróbel, K | 1 |
| Abazeed, M; Balynska, O; Desai, B; Dhawan, A; Durmaz, A; Haura, E; Kenian, L; Lozano-Peral, D; Marusyk, A; Marusyk, V; Mian, O; Miroshnychenko, D; Poleszhuk, J; Scott, J; Tan, AC; Teng, M; Vander Velde, R; Yoon, N | 1 |
| Cheng, H; Huang, LC; Kannan, N; Li, S; Ma, P; Rasheed, K; Venkat, A; Wang, Y; Yeung, W | 1 |
| Chen, K; Ni, J; Zhang, J; Zhang, X | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Goudopoulou, A; Kalogera-Fountzila, A; Kalogeras, KT; Karavasilis, V; Kouvatseas, G; Papadopoulos, G; Papandreou, CN; Rallis, G; Razis, E; Samantas, E; Syrigos, KN; Varaki, K | 1 |
| Bejjanki, H; Bishnoi, R; Reisman, D | 1 |
| Avogadri-Connors, F; Baselga, J; Berger, MF; Boni, V; Bryce, RP; Cai, Y; Chan, C; Chandarlapaty, S; Cocco, E; Cownie, J; Cutler, RE; Hyman, DM; Javier Carmona, F; Lalani, AS; Loi, S; Montemurro, F; Moriarty, A; Papadopoulos, KP; Razavi, P; Rossi, V; Sarotto, I; Savas, P; Scaltriti, M; Shifman, SG; Solit, DB; Soong, J; Toska, E; Wick, MJ; Won, HH | 1 |
| Balko, JM; Cook, RS; Elion, DL; Gonzales-Ericsson, PI; Hicks, DJ; James, JL; Koblish, HK; Nixon, MJ; Rahman, B; Sanchez, V; Scherle, PA; Werfel, TA | 1 |
| Hino, H; Hiramoto, M; Kazama, H; Lorenzo, A; Miyazawa, K; Moriya, S; Okuma, T; Ota, K; Takano, N; Yokota, A | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Blons, H; Chouaid, C; Cortot, AB; Dansin, E; Diebold, J; Felip, E; Gautschi, O; Lepage, B; Mansuet-Lupo, A; Mazières, J; Milia, JD; Moro-Sibilot, D; Peters, S; Rouquette, I; Urban, T; Wislez, M | 1 |
| Fan, YX; Johnson, GR; Marino, MP; Ou, W; Reiser, J; Shen, Y; Wong, KK; Wong, L; Wu, WJ | 1 |
| Bian, L; Jiang, Z; Wang, T; Zhang, S | 1 |
| Piccart, M | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Bendell, J; Burris, HA; Dowlati, A; Infante, JR; Jones, SF; Kane, MP; Levinson, KT; Stein, MN; Suttle, AB; Tan, AR | 1 |
| Bianco, R; D'Amato, C; D'Amato, V; Damiano, V; De Placido, S; Formisano, L; Iommelli, F; Marciano, R; Nappi, L; Parsons, SJ; Raimondo, L; Rosa, R; Scorziello, A; Troncone, G; Veneziani, B | 1 |
| Balansky, R; Camoirano, A; D'Agostini, F; De Flora, S; Ganchev, G; Iltcheva, M; Izzotti, A; La Maestra, S; Longobardi, M; Micale, RT; Steele, VE | 1 |
| Halmos, B; Hibshoosh, H; Jin, C; Li, G; Wang, X | 1 |
| Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Galli, G; Gevorgyan, A; Porcu, L; Serpico, D; Tessari, A; Torri, V | 1 |
| Wang, H; Yang, B; Zhang, H | 1 |
| Deeken, JF; He, AR; Hwang, J; Marshall, JL; Pishvaian, MJ; Ramos, C; Steadman, K; Subramaniam, D; Urso, CE; Wang, H; Wang, Y | 1 |
| Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L | 1 |
| Kaneko, T; Lau, MR; Lunec, J; Margetts, J; Novello, S; Nutt, J; Plummer, R; Ramlau, R; Reck, M; Scagliotti, GV; Thomas, M | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Maeda, A; Nakata, M; Nojima, Y; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Barlesi, F; Beau-Faller, M; Besse, B; Cappuzzo, F; Cortot, A; Dansin, E; Filleron, T; Fournel, P; Früh, M; Gautschi, O; Mazières, J; Milia, J; Monnet, I; Moro-Sibilot, D; Peters, S; Pless, M; Rosell, R; Westeel, V; Wislez, M | 1 |
| Chen, X; Ding, L; Jin, L; Liang, GK; Wu, HH; Yao, ZT; Zhang, JQ | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Aisner, J; Allen, KE; Blumenschein, GR; Damjanov, N; Dowlati, A; Garst, J; Hassani, H; Leopold, L; Rigas, JR; Ross, HJ; Shepherd, FA; Smylie, M; Zaks, TZ | 1 |
| Deng, X; Dewan, MZ; Kuroi, K; Saji, S; Takada, M; Terunuma, H; Toi, M; Yamamoto, N | 1 |
| Calvo, A; Catena, R; Collantes, M; Diaz, R; Díaz-González, JA; Manrique, I; Nguewa, PA; Parrondo, R; Peñuelas, I; Perez-Stable, C; Redrado, M | 1 |
| Bilici, A; Gumus, M; Kefeli, AU; Kefeli, U; Seker, M; Ustaalioglu, BB; Yildirim, ME | 1 |
| Hatch, H; Hirai, H; Kotani, H; Majumder, PK; Miyama, K; Nakatsuru, Y; Pan, BS; Sootome, H; Taguchi, S; Tsujioka, K; Ueno, Y | 1 |
| Breen, L; Clynes, M; Collins, DM; Dunne, G; O'Connor, R; Roche, S | 1 |
| Keane, MP; Kelly, E; McDonnell, TJ; Mhurchu, EN; Sukor, S; Tryfonopoulos, D | 1 |
| Aono, T; Iwase, K; Nakamura, Y; Nomura, M; Tanaka, Y | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B | 1 |
| Chew, HK; Christensen, S; Davies, AM; Gandour-Edwards, R; Gitlitz, B; Linden, H; Mack, PC; Solis, LJ; Somlo, G; Yang, X | 1 |
| Cole, PA; Head, S; Kim, K; Leahy, DJ; Longo, PA; Tarrant, MK; Wang, Z | 1 |
| Hirata, H; Inoue, K; Kida, H; Kijima, T; Kohmo, S; Kumanogoh, A; Minami, T; Nagatomo, I; Otani, Y; Suzuki, M; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Jain, A; Ryan, PD; Seiden, MV | 1 |
| Bastida, CC; Falchook, GS; Janku, F; Kurzrock, R; Stewart, DJ; Tsao, AS | 1 |
| Majem, M; Pallarès, C | 1 |
| Bonomi, P | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Alligood, K; Cable, L; Carter, HL; Gallagher, KT; Gilmer, TM; Rusnak, D; Shewchuk, L; Spehar, G; Truesdale, AT; Woldu, E; Wood, ER | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, SH; Kim, TY; Oh, DY | 1 |
| Blumenfeld, M; Farrar, W; Landon, MB; Pant, S; Shapiro, CL | 1 |
4 review(s) available for lapatinib and Cancer of Lung
| Article | Year |
|---|---|
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents.
Topics: Afatinib; Aminoquinolines; Angiogenesis Inhibitors; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2013 |
Clinical studies with non-iressa EGFR tyrosine kinase inhibitors.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Organic Chemicals; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Treatment Outcome | 2003 |
9 trial(s) available for lapatinib and Cancer of Lung
| Article | Year |
|---|---|
Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain; Brain Neoplasms; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Female; Follow-Up Studies; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2017 |
Trastuzumab plus capecitabine vs. lapatinib plus capecitabine in patients with trastuzumab resistance and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prospective Studies; Quinazolines; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Phase I study of weekly paclitaxel in combination with pazopanib and lapatinib in advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Humans; Indazoles; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Sulfonamides; Treatment Outcome | 2014 |
A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Biopsy; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Female; Genetic Variation; Genotype; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pharmacogenetics; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2015 |
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult | 2015 |
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Quinazolines; Thymidylate Synthase; Treatment Outcome | 2015 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
53 other study(ies) available for lapatinib and Cancer of Lung
| Article | Year |
|---|---|
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Synthesis and biological evaluation of pyrimidine-based dual inhibitors of human epidermal growth factor receptor 1 (HER-1) and HER-2 tyrosine kinases.
Topics: Acrylamides; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred ICR; Models, Molecular; Mutation; Oxazoles; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Stomach Neoplasms; Structure-Activity Relationship | 2012 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Nude; Peptides; Peptidomimetics; Phosphorylation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Transplantation, Heterologous | 2021 |
Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.
Topics: Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors | 2022 |
Based on lapatinib innovative near-infrared fluorescent probes targeting HER1/HER2 for in vivo tumors imaging.
Topics: Animals; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Colorectal Neoplasms; Fluorescent Dyes; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude | 2022 |
Study on the prognosis, immune and drug resistance of m6A-related genes in lung cancer.
Topics: Adenosine; Afatinib; Crizotinib; Dasatinib; Drug Resistance; Erlotinib Hydrochloride; Etoposide; Humans; Lapatinib; Lung Neoplasms; Tumor Microenvironment; Ubiquitin-Protein Ligases | 2022 |
Macrophages M2 polarization is involved in lapatinib-mediated chemopreventive effects in the lung cancer.
Topics: Humans; Interleukin-13; Lapatinib; Lung Neoplasms; Macrophages | 2023 |
Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Kidney Neoplasms; Lapatinib; Lung Neoplasms; Melanoma; Molecular Docking Simulation; Molecular Structure; Structure-Activity Relationship | 2023 |
Exploring the Potential of Lapatinib, Fulvestrant, and Paclitaxel Conjugated with Glycidylated PAMAM G4 Dendrimers for Cancer and Parasite Treatment.
Topics: Animals; Caenorhabditis elegans; Carcinoma, Non-Small-Cell Lung; Dendrimers; Fulvestrant; Glioma; Humans; Lapatinib; Lung Neoplasms; Paclitaxel; Parasites | 2023 |
Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mice; Polymorphism, Single Nucleotide; RNA-Seq; Single-Cell Analysis; Xenograft Model Antitumor Assays | 2020 |
Quantitative Structure-Mutation-Activity Relationship Tests (QSMART) model for protein kinase inhibitor response prediction.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Neural Networks, Computer; Precision Medicine; Protein Interaction Maps; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship | 2020 |
Inhibition of GPX4 or mTOR overcomes resistance to Lapatinib via promoting ferroptosis in NSCLC cells.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Ferroptosis; Gene Silencing; Humans; Lapatinib; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Phospholipid Hydroperoxide Glutathione Peroxidase; TOR Serine-Threonine Kinases | 2021 |
Novel Mutation Pair L858M/L861Q Caused Resistance to Both First- and Third-Generation EGFR Inhibitors, but Was Found to Be Sensitive to the Combination of Lapatinib and Erbitux.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lapatinib; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1.
Topics: Animals; Antineoplastic Agents; Apoptosis; c-Mer Tyrosine Kinase; Female; Indoleamine-Pyrrole 2,3,-Dioxygenase; Inflammation; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Necrosis; Phagocytosis; Receptor, ErbB-2; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2019 |
Fingolimod sensitizes EGFR wild‑type non‑small cell lung cancer cells to lapatinib or sorafenib and induces cell cycle arrest.
Topics: A549 Cells; Autophagy-Related Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fingolimod Hydrochloride; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Sorafenib | 2019 |
Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; France; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutagenesis, Insertional; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Spain; Switzerland; Trastuzumab; Treatment Outcome | 2013 |
Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Amino Acid Substitution; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity | 2013 |
Personalised cancer management: closer, but not here yet.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Molecular Targeted Therapy; Precision Medicine; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2013 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transplantation, Heterologous | 2014 |
Assay of lapatinib in murine models of cigarette smoke carcinogenesis.
Topics: Animals; Antineoplastic Agents; Body Weight; Disease Models, Animal; DNA Adducts; DNA Damage; Erythrocytes; Gene Expression Regulation; Lapatinib; Lung; Lung Neoplasms; Mice; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Tobacco Smoke Pollution; Toxicity Tests, Subchronic | 2014 |
Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; MCF-7 Cells; Mutagenesis, Site-Directed; Mutation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transcription Factors | 2014 |
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine.
Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2014 |
Disease progression pattern in metastatic breast cancer patients treated with anti-HER2 therapies.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Central Nervous System Neoplasms; Disease Progression; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Middle Aged; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Time Factors; Trastuzumab; Treatment Outcome | 2015 |
Atomistic insights into the lung cancer-associated L755P mutation in HER2 resistance to lapatinib: a molecular dynamics study.
Topics: Alleles; Amino Acid Substitution; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Lapatinib enhances trastuzumab-mediated antibody-dependent cellular cytotoxicity via upregulation of HER2 in malignant mesothelioma cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease-Free Survival; ErbB Receptors; Europe; Female; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Retrospective Studies; Trastuzumab; Treatment Outcome | 2016 |
[Combination of lapatinib with chlorogenic acid inhibits breast cancer metastasis by suppressing macrophage M2 polarization].
Topics: Animals; Chlorogenic Acid; Female; Lapatinib; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mice; Neoplasm Metastasis; Quinazolines | 2015 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Killer Cells, Natural; Lapatinib; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Trastuzumab | 2011 |
Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Replication; Dose-Response Relationship, Drug; Endothelial Cells; ErbB Receptors; Gene Amplification; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Stem Cells; Time Factors; Xenograft Model Antitumor Assays | 2010 |
A case of metastatic breast cancer successfully treated with lapatinib plus capecitabine therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Quinazolines | 2011 |
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; Lung Neoplasms; Mice; Molecular Structure; Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Modulation of P-gp expression by lapatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Squamous Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2011 |
Chemotherapy-associated recurrent pneumothoraces in lymphangioleiomyomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Lapatinib; Lung Neoplasms; Lymphangioleiomyomatosis; Middle Aged; Neoplasms, Second Primary; Oxygen Inhalation Therapy; Pneumothorax; Quinazolines; Trastuzumab | 2010 |
[Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Lung Neoplasms; Lymph Node Excision; Mastectomy; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2010 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Trastuzumab and chemotherapy after the treatment failure of lapatinib for HER2-positive metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Female; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Failure | 2010 |
Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Epidermal Growth Factor; ErbB Receptors; HEK293 Cells; Humans; Kinetics; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Quinazolines; Tumor Suppressor Proteins | 2011 |
HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Small Cell Lung Carcinoma; Transfection; Up-Regulation | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Metastatic mucinous ovarian cancer and treatment decisions based on histology and molecular markers rather than the primary location.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Cystadenocarcinoma, Mucinous; ErbB Receptors; Female; Humans; Lapatinib; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factors; Young Adult | 2012 |
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Exons; Female; Humans; Lapatinib; Lung Neoplasms; Middle Aged; Mutation; Prognosis; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vascular Endothelial Growth Factor A | 2013 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutant Proteins; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chlorocebus aethiops; COS Cells; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Mutation; Quinazolines | 2008 |
Treatment of breast cancer with trastuzumab during pregnancy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Infant, Low Birth Weight; Infant, Newborn; Infant, Premature; Lapatinib; Lung Neoplasms; Mastectomy, Modified Radical; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Quinazolines; Trastuzumab | 2008 |